Department of Health and Human Services June 23, 2023 – Federal Register Recent Federal Regulation Documents
Results 1 - 9 of 9
Notice of Non-Federal Funds Reported by State/Jurisdiction Awardees on the Maternal, Infant, and Early Childhood Home Visiting Program for the Purposes of Meeting Maintenance of Effort Requirements (2019 and 2021)
HRSA announces the publication of the amount of non-Federal funds each Maternal, Infant, and Early Childhood Home Visiting Program state/jurisdiction awardee has reported expending for fiscal years (FY) 2019 and 2021 for the purposes of meeting maintenance of effort requirements under this provision.
Request for Information (RFI) on NIDCD's Research Directions To Support Communication in Minimally Verbal/Non-Speaking People
The National Institute on Deafness and Other Communication Disorders (NIDCD) asks for input on research directions to support communication in minimally verbal/non-speaking people. NIDCD invites anyone with interests in communication in minimally verbal/non-speaking people to provide input from a personal, service delivery, or research view. Responses to this RFI will be used for planning purposes. The NIDCD will use the information submitted in response to this RFI at its discretion and will not provide comments to any responder's submission.
Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act.'' This draft guidance provides recommendations for industry and review staff on the formal dispute resolution and administrative hearings procedures for resolving scientific and/or medical disputes between the Center for Drug Evaluation and Research (CDER) and requestors and sponsors of drugs that will be subject to a final administrative order (final order) under section 505G of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Advisory Committee; Medical Imaging Drugs Advisory Committee; Renewal
The Food and Drug Administration (FDA) is announcing the renewal of the Medical Imaging Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Medical Imaging Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 18, 2025, expiration date.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
